Edition:
United States

Carlyle Group LP (CG.O)

CG.O on Nasdaq

19.35USD
23 Jun 2017
Change (% chg)

$0.05 (+0.26%)
Prev Close
$19.30
Open
$19.20
Day's High
$19.35
Day's Low
$19.15
Volume
278,534
Avg. Vol
688,875
52-wk High
$19.35
52-wk Low
$14.35

CG.O

Chart for CG.O

About

The Carlyle Group L.P. is a diversified multi-product global alternative asset management firm. The Company operates in four segments: Corporate Private Equity (CPE), Real Assets, Global Market Strategies (GMS) and Investment Solutions. Corporate Private Equity advises its buyout and growth capital funds, which pursue various... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $6,323.96
Shares Outstanding(Mil.): 327.67
Dividend: 0.10
Yield (%): 8.55

Financials

  CG.O Industry Sector
P/E (TTM): 22.16 139.17 29.76
EPS (TTM): 0.87 -- --
ROI: 5.82 6.26 0.46
ROE: 20.12 11.17 15.84

BRIEF-Carlyle Group enters London flexible office and co-working sector

* Carlyle Group enters London flexible office and co-working sector with commitment to invest £150 million into launch of ‘uncommon’ brand

Jun 16 2017

LPC: Familiar Veritas comes full circle with US repricing effort

NEW YORK, June 13 Nearly a year to the day after banks finally sold the loans backing Veritas Software’s buyout at a discount of 85 cents on the dollar, the issuer is back in market with an effort to lower the interest rate on the debt.

Jun 13 2017

Valeant looks to trim debt pile with $930 million iNova sale

Valeant Pharmaceuticals International Inc said on Thursday it would sell its iNova Pharmaceuticals business for $930 million, as Chief Executive Joseph Papa steps up efforts to slash the embattled Canadian drugmaker's enormous debt pile.

Jun 08 2017

Deals of the day-Mergers and acquisitions

June 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: ** Canadian drugmaker Valeant Pharmaceuticals International Inc is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG, Bloomberg reported.

Jun 06 2017

GTCR, Carlyle to buy contract research firm Albany Molecular

Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash.

Jun 06 2017

UPDATE 4-GTCR, Carlyle to buy contract research firm Albany Molecular

* Albany Molecular shares jump as much as 8.9 pct (Adds analyst comment)

Jun 06 2017

BRIEF-AMRI to be acquired by the Carlyle Group and GTCR

* AMRI signs definitive agreement to be acquired by the Carlyle Group and GTCR for $21.75 per share in cash

Jun 06 2017

GTCR, Carlyle to buy contract research firm Albany Molecular

June 6 Contract research company Albany Molecular Research Inc said on Tuesday it would be bought by private equity firms Carlyle Group LP and GTCR LLC for about $922 million in cash.

Jun 06 2017

Fitch Upgrades Bank of N.T. Butterfield & Son Ltd.'s Viability Rating to 'bbb'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, May 22 (Fitch) Fitch Ratings has upgraded the Bank of N.T. Butterfield & Son Limited's (BNTB) Viability Rating (VR) to 'bbb' from 'bbb-' following its review of the bank. Fitch has also affirmed BNTB's support-driven Long-Term Issuer Default Rating (IDR) of 'BBB'. The Rating Outlook remains Stable. A full list of rating actions follows at the end of this press release. KEY RATING DRIVERS VR Today's upgrade reflects BNTB's demo

May 22 2017

BRIEF-Carlyle and EOG Resources announce $400 mln drilling partnership

* Carlyle and EOG Resources announce $400 million drilling partnership

May 22 2017

More From Around the Web

Earnings vs. Estimates